Table 2 Haematological parameters of trial participants at baseline (N = 167)
From: Haematological and fibrinolytic status of Nigerian women with post-partum haemorrhage
n a | Mean (SD) / Count (%) | Median (25th, 75th centile range) | Normal rangeb | |
|---|---|---|---|---|
Full Blood Count Variables | ||||
Red blood cell count (×10^12/L) | 130 | 2.9 (1.0) | 3.0 (2.3, 3.7) | 3.8–5.8 |
Haemoglobin (g/L) | 132 | 78.1 (35.6) | 79.5 (56, 97) | 110–165 |
Haemoglobin < 110 g/L | 116 (87.9%) | |||
Microcytic (MCV < 80) | 38 (32.8%) | |||
Normocytic (MCV 80–100) | 75 (64.7%) | |||
Macrocytic (MCV > 100) | 3 (2.6%) | |||
Haemoglobin < 70 g/L | 53 (40.2%) | |||
Hematocrit (%) | 127 | 24.2 (7.7) | 24.7 (19.2, 30) | 35–50 |
Hematocrit < 33% | 109 (85.8%) | |||
Hematocrit < 25% | 64 (50.4%) | |||
White cell count (×10^9/L) | 131 | 11.9 (8.1) | 11.2 (5.3, 16.9) | 3.5–10.0 |
White cell count > 25 (×10^9/L) | 8 (6.1%) | |||
Lymphocyte count (×10^9/L) | 122 | 2.6 (2.4) | 1.9 (1, 3) | 1.2–3.2 |
Lymphocyte count < 1 (×10^9/L) | 26 (21.3%) | |||
Differential white cell count (monocytes) (×10^9/L) | 100 | 1.8 (1.8) | 1.3 (0.6, 2.2) | 0.3–0.8 |
Differential white cell count (granulocytes) (×10^9/L) | 100 | 8.7 (5.6) | 7.7 (5.1, 11.5) | 1.2–6.8 |
Platelet count (×10^9/L) | 130 | 155.2 (101.7) | 137 (86, 208) | 150–390 |
Platelet count < 100 (×10^9/L) | 41 (31.5%) | |||
Platelet count < 50 (×10^9/L) | 17 (13.1%) | |||
Coagulation variables | ||||
Prothrombin time (PT, seconds) | 137 | 19.0 (12.6) | 15.2 (13.5, 18.8) | 9.6–12.9 |
Normalised prothrombin ratio | 133 | 1.2 (0.7) | 1.0 (0.9, 1.2) | |
Normalised prothrombin ratio > 1.2 | 29 (21.8%) | |||
Normalised prothrombin ratio > 1.5 | 16 (12.0%) | |||
Activated partial thromboplastin time (APTT, seconds) | 133 | 35.9 (22.9) | 30.4 (27.1, 35.6) | |
Thrombin time (TT, seconds) | 124 | 13.1 (12.5) | 10.4 (9.1, 12.6) | |
Normalised thrombin ratio | 124 | 0.9 (0.9) | 0.7 (0.6, 0.9) | |
Fibrinogen (g/L) | 136 | 8.4 (6.6) | 6.6 (3.2, 12.3) | |
Fibrinogen (< 1 g/L) | 4 (2.9%) | |||
Fibrinogen (< 2 g/L) | 16 (11.8%) | |||
Fibrinogen (< 4 g/L) | 45 (33.1%) | |||
D-Dimer (mg/L) | 119 | 8.6 (8.2) | 5.7 (2.3, 13.5) | |
Thromboelastometry (ROTEM® EXTEM) variables | ||||
Clotting time (CT, seconds) | 151 | 127.4 (336.9) | 54 (45, 72) | 34–66 |
Amplitude at 5 mins (A5, mm) | 146 | 42.1 (15.8) | 47 (35, 53) | |
A5 < 40 mm | 49 (33.6%) | |||
Amplitude at 10 mins (A10, mm) | 149 | 51.6 (17.5) | 58 (47, 63) | 44–73 |
Maximum clot firmness (MCF, mm) | 146 | 59.3 (17.5) | 65 (56, 70) | 55–78 |
Clot lysis at 30 min (LI30, %) | 145 | 98.0 (10.8) | 100 (100, 100) | |
Clot lysis at 60 min (LI60, %) | 101 | 93.3 (10.1) | 96 (92, 99) | |
Maximum Lysis (ML, %) | 150 | 14.7 (20.4) | 9 (4, 15) | 0–44 |
ML > 15% | 35 (23.3%) | |||
Thromboelastometry (ROTEM® APTEM) variables | ||||
Clotting time (CT, seconds) | 152 | 245.2 (882.3) | 58 (46, 81) | 31–71 |
Amplitude at 5 mins (A5, mm) | 143 | 44.0 (15.2) | 48 (35, 54) | |
A5 < 40 mm | 49 (33.6%) | |||
Amplitude at 10 mins (A10, mm) | 147 | 52.9 (16.8) | 59 (46, 64) | 43–72 |
Maximum clot firmness (MCF, mm) | 144 | 61.4 (15.6) | 67 (58, 71) | 56–78 |
Maximum Lysis (ML, %) | 147 | 5.9 (5.7) | 5 (2, 8) | 0–14 |